ScripWhile 2023 saw several cell and gene therapy approvals that were genuine scientific and clinical breakthroughs, many smaller companies in the sector bore the brunt of the ongoing biopharma downturn. M
ScripVenture capital mega-rounds of $100m or more – like the $245m series A round that Aiolos Bio Inc. announced on 24 October – have played a big part in surging quarterly and annual totals of biopharma
ScripPluvicto is forecast to be Novartis AG ’s fourth biggest-selling drug in 2028, with worldwide sales of $3.4bn according to Evaluate Pharma consensus data, but this figure might have to be revised d
In VivoOphthalmic gene therapy company Beacon Therapeutics was launched in June 2023 with a £96m ($120m) series A financing. The company was created by VC firm Syncona Investment Management, which combined A